Clinical trial
PREvent First Episode Relapse (PREFER)
NCT00220714 · State University of New York - Downstate Medical Center, Other · Unknown status
Key facts
| NCT number | NCT00220714 |
|---|---|
| Title | PREvent First Episode Relapse (PREFER) |
| Official title | Effectiveness of Long-Acting Risperidone in the Maintenance Treatment of First-Episode Schizophrenia |
| Lead sponsor | State University of New York - Downstate Medical Center, Other |
| Collaborators | Janssen, LP Industry |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Behavioral, Drug |
| Interventions | atypical antipsychotics:oral vs. long-acting route, Family Psychoeducation |
| Enrollment | 80 |
| Start date | Nov 1, 2004 |
| Completion | Dec 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Mar 31, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: